By using the (CRISPR)/Cas9 technology, they demonstrated that the simultaneous inactivation of CDKN2A, CDKN2B, and TP53 in primary TCL1 transgenic-derived murine CLL cells induces proliferation in vitro and accelerates tumor growth in the TCL1 tg transplantation system. Here, CDKN2B is linked to B-cell chronic lymphocytic leukemia.